Use of latanoprost in the treatment of glaucoma associated with Sturge- Weber syndrome
DOI 10.1016/S0002-9394(98)00129-9
C.B. Yang, S.F. Freedman, and J.S. Myers Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome Am J Ophthalmol 126 1998 600 602 (Pubitemid 28475930)
Reappraisal of the human ocular growth curve in fetal life, infancy, and early childhood
H.C. Fledelius, and A.C. Christensen Reappraisal of the human ocular growth curve in fetal life, infancy, and early childhood Br J Ophthalmol 80 1996 918 921 (Pubitemid 26366563)
Ontogeny of hepatic and renal systemic clearance pathways in infants: Part I
J. Alcorn, and P.J. McNamara Ontogeny of hepatic and renal systemic clearance pathways in infants: part I Clin Pharmacokinet 41 2002 959 998 (Pubitemid 35168438)
Regulation (EC) No. 1901/2006 of the European Parliament and of the Council, of 12 December 2006, on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC, and Regulation (EC) No. 726/2004 http://eur-lex.europa.eu/ LexUriServ/site/en/consleg/2006/R/02006R1901-20070126-en.pdf Accessed August 25, 2010
Pfizer and Upjohn Co New York Accessed February 11, 2011
Xalatan: latanoprost ophthalmic solution [package insert] 2009 Pfizer and Upjohn Co New York http://www.pfizer.com/files/products/uspi-xalatan-multi.pdf Accessed February 11, 2011